In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Biogen Idec, Eisai sign multi-drug deal in the area of Alzheimer's disease

Executive Summary

To further enhance its strong neurodegenerative disease pipeline, Biogen Idec Inc. will co-develop and co-commercialize two of Eisai Co. Ltd.'s Alzheimer’s disease candidates--the Phase II-ready ß-site amyloid precursor protein cleaving enzyme (BACE) inhibitor E2609 and Phase II BAN2401, an anti-amyloid beta (Aß) antibody. In addition, Eisai has the option to jointly develop and commercialize two of Biogen’s AD candidates--the Phase Ib Aß antibody BIIB037 and preclinical BIIB076, an anti-tau monoclonal antibody.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Marketing
    • Includes Royalty or Profit Split Information
    • Product or Technology Swap
    • R&D and Marketing (Licensing)
    • Reverse Licensing

Related Companies